Animal Models of Deep Vein Thrombosis (DVT)

DVT models reproduce Virchow’s triad by mechanically or chemically inducing thrombus formation in large veins, most commonly the inferior vena cava (IVC). These systems yield quantifiable endpoints (thrombus weight, length, histopathology, and vein wall remodeling), enabling robust mechanistic dissection and dose‑finding under controlled, reproducible conditions.

Download

Key Preclinical Application Areas

Anticoagulant Drug Development: Screening of direct oral anticoagulants (factor Xa inhibitors, thrombin inhibitors), heparin derivatives, and novel agents targeting FXIa or FIXa.
Antiplatelet and Anti‑inflammatory Combination Strategies: Evaluation of P2Y12 inhibitors, GPIIb/IIIa antagonists, and immunomodulators (e.g., IL‑1β blockers, colchicine) in reducing venous thrombus propagation and vein wall inflammation.
Thrombolytic and Fibrinolytic Therapies: Testing of tPA variants, urokinase, and novel plasminogen activators. Determination of recanalization kinetics, resistance, and re‑thrombosis windows.
Chronic Venous Remodeling & Post‑thrombotic Syndrome: Longitudinal studies assessing organized thrombus, collagen deposition, neovascularization, and wall fibrosis using histomorphometry and molecular markers.
Embolic Risk and Pulmonary Embolism modeling: Extended monitoring for clot fragmentation and distal embolization via lung histology or imaging, providing critical safety endpoints for pro‑thrombolytic candidates.

Animal Models of Deep Vein Thrombosis (DVT)

Fill In This Form to Get Details of Our Case Studies.

Animal Models of Deep Vein Thrombosis (DVT)

You might be interested in...